This post was originally published on this site
PARIS (Reuters) – Sanofi (NASDAQ:SNY) raised its 2021 outlook after its vaccines and star eczema treatment Dupixent helped it post better-than-expected second-quarter results on Thursday.
The French drugmaker said it was now targeting earnings per share to grow around 12% at constant exchange rates this year. It had previously been expecting a “high single digit” rise in earnings.
